Event Timeline
| 11:15 AM - 11:21 AM PDT |
Speaker |
Efficacy and Safety of Flexible-Dose Tavapadon, an Orally Administered, Once-Daily, Selective D1/D5 Partial Dopamine Agonist for the Treatment of Early Parkinson’s Disease
|
| 11:21 AM - 11:27 AM PDT |
Speaker |
Efficacy and Safety of Fixed-Dose Tavapadon, an Oral, Once-Daily, Selective D1/D5 Partial Dopamine Agonist for the Treatment of Early Parkinson’s Disease
|
| 11:27 AM - 11:33 AM PDT |
Speaker |
Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
|
| 11:33 AM - 11:39 AM PDT |
Speaker |
Intravenous Fosphenytoin Therapy for Acute Trigeminal Neuralgia: A Phase 3 Randomized Clinical Trial (IFT Study)
|
| 11:39 AM - 11:45 AM PDT |
Speaker |
A Holistic Spinal Cord Stimulation Approach To Treat Painful Diabetic Peripheral Neuropathy: The Inspire Study
|
| 11:45 AM - 11:51 AM PDT |
Speaker |
Mi-Helper Transnasal Cooling for Acute Migraine Treatment: A Prospective, Double-blind, Randomized, Sham-controlled, Decentralized Dosing Study
|
| 11:51 AM - 11:57 AM PDT |
Speaker |
Multi-ancestry Genome-wide Analysis of 90,600 Migraine Cases in US Veterans
|
| 11:57 AM - 12:03 PM PDT |
Speaker |
Safety, Tolerability and Efficacy of ALMB-0166 in the Patients with Acute Spine Cord Injury (SCI): A Multicenter, Randomized, Placebo-controlled, Phase I/II Study
|
| 12:03 PM - 12:09 PM PDT |
Speaker |
ARIA Risk Factors and Management Experience in Donanemab Clinical Trials in Early Symptomatic Alzheimer's Disease
|
| 12:09 PM - 12:45 PM PDT |
Q&A |
Poster Q&A
|